Ocular Therapeutix Inc. (Nasdaq: OCUL) reported disappointing results from a
second Phase 3 clinical trial of its ocular inflammation and pain
treatment OTX-DP sending the stock price plummeting $7.25 to close at $31.05.
Disappointing trial results for Ocular Therapeutix
April 07, 2015 at 16:48 PM EDT
